logo
  

GEA Group Q2 Profit, Orders Climb; Raises FY21 View; To Buy Back EUR 300 Mln Shares

German food and beverages company GEA Group AG (GEAGF.PK,GEAGY.PK) reported Friday that its second-quarter profit climbed 70 percent to 76.9 million euros from previous year's 45.2 million euros.

Earnings per share increased to 0.43 euro from 0.25 euro in the second quarter.

EBITDA before restructuring expenses went up 9.4 percent from last year to 153.7 million euros. EBITDA margin before restructuring expenses raised 1.2 percentage points to 13.3 percent.

GEA's revenue was 1.156 billion euros, down 0.8 percent from last year's 1.165 billion euros. In organic terms, however, revenue grew 3.4 percent.

In the second quarter, order intake rose 25.1 percent to 1.29 billion euros from 1.034 billion euros last year with growth in all divisions and regions. On an organic basis, the improvement was 30.2 percent.

Further, GEA significantly raised its outlook for fiscal year 2021. The company now expects organic revenue growth of 5 to 7 percent, compared to previously expected 0 to 5 percent.

EBITDA before restructuring expenses at constant exchange rates is now expected to be in a range between 600 million euros and 630 million euros, compared to previously expected between 530 million euros and 580 million euros.

The company also announced share buyback program with a volume of up to 300 million euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT